DYN Smart Money
Dyne Therapeutics, Inc.
1W: +4.1%
1M: +3.7%
3M: -32.5%
YTD: -8.4%
1Y: -1.1%
3Y: +133.7%
5Y: +17.5%
$16.94
+1.22 (+7.76%)
Weekly Expected Move ±7.8%
$13
$14
$16
$17
$18
Credit Risk of going bust: lower than 67% of companies Debt: 0.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.02 (down 99.9%), Dyne Therapeutics, Inc. would be worth roughly what it owes.
Total debt $19.9M against a stock market value of $3.16B.
Distance to default 7.09 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $12.6M (short-term plus half of long-term), stock volatility 74.9%; Altman Z'' -0.72. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.02 (down 99.9%), Dyne Therapeutics, Inc. would be worth roughly what it owes.
Total debt $19.9M against a stock market value of $3.16B.
Distance to default 7.09 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $12.6M (short-term plus half of long-term), stock volatility 74.9%; Altman Z'' -0.72. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
🏦 Institutional Activity
Latest: Q2 2026277
Institutions Holding
+6 vs prior
110.0%
Ownership
+21.50%
50
New
89
Increased
105
Reduced
29
Closed
👔 Insider Trades
25 records| Date | Name | Title | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-20 | Kerr Douglas | officer: head of r&d and cmo | A-Grant/Award | 8,000 | $— | $0 | Filing |
| 2026-10-02 | Posner Brian S | director | P-Purchase | 2,500 | $16.00 | $40K | Filing |
| 2026-09-08 | Friedl-Naderer Johanna | officer: chief commercial officer | S-Sale | 185 | $18.88 | $3K | Filing |
| 2026-09-08 | Kerr Douglas | officer: chief medical officer | S-Sale | 1,290 | $18.88 | $24K | Filing |
| 2026-09-08 | Cox John | officer: ceo & president | S-Sale | 5,658 | $18.88 | $107K | Filing |
| 2026-09-04 | Friedl-Naderer Johanna | officer: chief commercial officer | S-Sale | 900 | $24.35 | $22K | Filing |
| 2026-09-04 | Kerr Douglas | officer: chief medical officer | S-Sale | 3,745 | $24.35 | $91K | Filing |
| 2026-08-14 | Rhodes Jason P | director | S-Sale | 478,377 | $25.00 | $12.0M | Filing |
| 2026-08-14 | Rhodes Jason P | director | S-Sale | 1,359,674 | $25.00 | $34.0M | Filing |
| 2026-08-14 | Rhodes Jason P | director | S-Sale | 322,465 | $25.00 | $8.1M | Filing |
| 2026-08-13 | Rhodes Jason P | director | S-Sale | 268,354 | $26.20 | $7.0M | Filing |
| 2026-08-13 | Rhodes Jason P | director | S-Sale | 94,415 | $26.20 | $2.5M | Filing |
| 2026-08-13 | Rhodes Jason P | director | S-Sale | 63,643 | $26.20 | $1.7M | Filing |
| 2026-08-13 | Cox John | officer: ceo & president | S-Sale | 4,986 | $26.28 | $131K | Filing |
| 2026-08-13 | Lucera Erick | officer: chief financial officer | S-Sale | 1,797 | $26.28 | $47K | Filing |
| 2026-08-13 | Kerr Douglas | officer: chief medical officer | S-Sale | 1,556 | $26.28 | $41K | Filing |
| 2026-08-13 | Friedl-Naderer Johanna | officer: chief commercial officer | S-Sale | 226 | $26.28 | $6K | Filing |
| 2026-07-27 | Kersten Dirk | director | S-Sale | 5,388 | $26.04 | $140K | Filing |
| 2026-07-27 | Kersten Dirk | director | S-Sale | 256,072 | $25.50 | $6.5M | Filing |
| 2026-07-07 | Rhodes Jason P | director | S-Sale | 62,543 | $23.17 | $1.4M | Filing |
| 2026-07-07 | Rhodes Jason P | director | S-Sale | 5,000 | $23.61 | $118K | Filing |
| 2026-07-07 | Rhodes Jason P | director | S-Sale | 49,193 | $23.17 | $1.1M | Filing |
| 2026-07-07 | Rhodes Jason P | director | S-Sale | 14,844 | $23.62 | $351K | Filing |
| 2026-07-07 | Rhodes Jason P | director | S-Sale | 29,587 | $23.62 | $699K | Filing |
| 2026-07-07 | Rhodes Jason P | director | S-Sale | 124,379 | $23.17 | $2.9M | Filing |
🏛️ Congressional Trades
0 records| Date | Politician | Chamber | Type | Amount | Filing |
|---|---|---|---|---|---|
| No congressional trades found | |||||
🏦 Top Institutional Holders
20 holders| Holder | Shares | Value | Date Reported | Filing | |
|---|---|---|---|---|---|
| BlackRock, Inc. | 12,404,330 | $276M | +704,460 | 2026-06-30 | Filing |
| Jupiter Topco LLC | 11,997,738 | $267M | +11,997,738 | 2026-06-30 | Filing |
| FMR LLC | 11,207,000 | $249M | +2,298,020 | 2026-06-30 | Filing |
| STATE STREET CORP | 7,458,263 | $166M | +804,517 | 2026-06-30 | Filing |
| Orbis Allan Gray Ltd | 7,006,542 | $156M | +244,311 | 2026-06-30 | Filing |
| Atlas Venture Life Science Advisors, LLC | 6,800,099 | $151M | -2,330,366 | 2026-06-30 | Filing |
| VANGUARD CAPITAL MANAGEMENT LLC | 6,310,969 | $140M | -94,100 | 2026-06-30 | Filing |
| TCG Crossover Management, LLC | 4,615,144 | $103M | — | 2026-06-30 | Filing |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4,048,428 | $90M | -113,613 | 2026-06-30 | Filing |
| FCPM III SERVICES B.V. | 3,848,256 | $85M | -796,130 | 2026-06-30 | Filing |
| GEODE CAPITAL MANAGEMENT, LLC | 3,743,427 | $83M | +239,313 | 2026-06-30 | Filing |
| Vestal Point Capital, LP | 3,375,000 | $75M | -625,000 | 2026-06-30 | Filing |
| ORBIMED ADVISORS LLC | 3,235,684 | $72M | +317,800 | 2026-06-30 | Filing |
| Frazier Life Sciences Management, L.P. | 3,153,082 | $70M | — | 2026-06-30 | Filing |
| ARMISTICE CAPITAL, LLC | 3,087,226 | $69M | -87,884 | 2026-06-30 | Filing |
| JPMORGAN CHASE & CO | 3,151,656 | $67M | -101,817 | 2026-06-30 | Filing |
| PERCEPTIVE ADVISORS LLC | 2,689,235 | $60M | -1,979,604 | 2026-06-30 | Filing |
| Logos Global Management LP | 2,550,000 | $57M | +1,150,000 | 2026-06-30 | Filing |
| BANK OF AMERICA CORP /DE | 2,233,398 | $50M | +790,085 | 2026-06-30 | Filing |
| Venrock Adviser, LLC | 2,173,913 | $48M | — | 2026-06-30 | Filing |